Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene Expression Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

NCT02055365
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

NCT00436254
View directory record Official record
Conditions
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
pNGVL3-hICD vaccine, sargramostim, flow cytometry, immunologic technique, immunoenzyme technique, protein expression analysis, biopsy
Biological · Other · Genetic + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Survival Prolongation by Rationale Innovative Genomics

NCT03386929
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Interventions
Avelumab, Axitinib, Palbociclib
Drug
Lead sponsor
Worldwide Innovative Network Association
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 20, 2026, 5:26 AM EDT
Completed No phase listed Observational

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

NCT04721002
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
New Orleans, Louisiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 20, 2026, 5:26 AM EDT
Active, not recruiting Phase 2 Interventional

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

NCT01352520
View directory record Official record
Conditions
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma, Cutaneous Lymphomas, Lymphoma, Hematologic Disorder
Interventions
SGN-35
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988
View directory record Official record
Conditions
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
Interventions
Mirvetuximab Soravtansine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Sarasota, Florida • Edgewood, Kentucky • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Enrolling by invitation No phase listed Observational

RNA Assays for Endometriosis Detection and Diagnosis

NCT06907303
View directory record Official record
Conditions
Endometriosis
Interventions
EndoDx
Diagnostic Test
Lead sponsor
Wren Laboratories LLC
Industry
Eligibility
20 Years to 35 Years · Female only
Enrollment
400 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

NCT04471727
View directory record Official record
Conditions
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions
Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
Biological
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional

Positive Processes and Transition to Health - Single-Session (PATH-SS)

NCT06900712
View directory record Official record
Conditions
PTSD, Depression
Interventions
PATH-SS
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional Results available

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04027946
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung
Interventions
LMB-100, pembrolizumab, Mesothelin Expression, TrueSight Oncology 500
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 20, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions
Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Completed No phase listed Observational

Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children

NCT00308906
View directory record Official record
Conditions
Infection, Renal Dysfunction
Interventions
aminoglycoside
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 18 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 20, 2026, 5:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetics of Muscle Insulin Resistance

NCT03259984
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

NCT00052611
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 20, 2026, 5:26 AM EDT
Terminated Phase 1 Interventional

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions
FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors

NCT01504932
View directory record Official record
Conditions
Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
BRB Lozenge, Survey Administration, Laboratory Biomarker Analysis, pharmacological study
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 20, 2026, 5:26 AM EDT
Withdrawn No phase listed Observational

Bariatric Surgery Outcomes

NCT01057784
View directory record Official record
Conditions
Morbid Obesity
Interventions
Bariatric surgery.
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 20, 2026, 5:26 AM EDT
Recruiting Phase 1 Interventional

CD4^LVFOXP3 in Participants With IPEX

NCT05241444
View directory record Official record
Conditions
IPEX
Interventions
CD4^LVFOXP3
Biological
Lead sponsor
Bacchetta, Rosa, MD
Other
Eligibility
4 Months to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Completed No phase listed Observational

Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern

NCT01251302
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions
Corus CAD (ASGES)
Diagnostic Test
Lead sponsor
CardioDx
Industry
Eligibility
21 Years to 99 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 20, 2026, 5:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Uveitis Gene-Expression Profiling

NCT00874471
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 20, 2026, 5:26 AM EDT
Completed No phase listed Observational

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

NCT06314971
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Neoplasms Malignant, Colorectal Cancer Recurrent
Interventions
Tw1CE
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 1Phase 2 Interventional

Study of DF1001 in Patients With Advanced Solid Tumors

NCT04143711
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional

RECONsolidation of Traumatic Memories to ResOLve Post Traumatic Stress Disorder (RECONTROLPTSD)

NCT03827057
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Reconsolidation of Traumatic Memories (RTM), Prolonged Exposure (PE)
Behavioral
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Not listed Phase 4 Interventional

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

NCT04529512
View directory record Official record
Conditions
Ocular Disease Requiring Surgery
Interventions
DEXTENZA®
Drug
Lead sponsor
Nathan Steinle
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Paso Robles, California • San Luis Obispo, California • Santa Maria, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 20, 2026, 5:26 AM EDT